Progressive multifocal leukoencephalopathy (PML) is the most feared complication when
natalizumab (NTZ) is used in the treatment of relapsing multiple sclerosis (MS). The risk of
PML increases after 18 months of treatment. When switching from NTZ to another disease
modifying treatment (DMT) in these MS patients with an active disease, there is a high risk
of inflammatory reactivation. Nonetheless, a washout period of several weeks is necessary
before initiating a new DMT.
The primary purpose of this protocol is to investigate the impact of high dose of oral
methylprednisolone, given once a month during the washout period between NTZ and Fingolimod